Nesiritide during extracorporeal membrane oxygenation

Paediatric Anaesthesia

Volumn 15, Issue 2, 2005, Pages 152-157

  Smith, Todd ^a   Rosen, David A ^b,c   Russo, Pierantonio ^d   Berkenbosch, John W ^a   Gustafson, Robert A ^c   Siu, Benjamin L ^b   Rosen, Kathleen R ^b,c   Tobias, Joseph D ^a  

^a University of Missouri   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

Author keywords

B type natriuretic peptide; Congenital heart disease; Extracorporeal membrane oxygenation; Nesiritide

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; NESIRITIDE;

ARTICLE; CASE REPORT; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG FORMULATION; DRUG USE; EXTRACORPOREAL OXYGENATION; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; MALE; MEAN ARTERIAL PRESSURE; NEWBORN; PRIORITY JOURNAL; URINE VOLUME;

BLOOD PRESSURE; CARDIOPULMONARY RESUSCITATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; EXTRACORPOREAL MEMBRANE OXYGENATION; FATAL OUTCOME; HEART DISEASES; HEART VENTRICLES; HERNIA, DIAPHRAGMATIC; HUMANS; HYPERTENSION; HYPOKINESIA; HYPOPLASTIC LEFT HEART SYNDROME; INFANT, NEWBORN; MALE; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; RESPIRATORY INSUFFICIENCY; URINATION;

EID: 13944253661     PISSN: 11555645     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1460-9592.2004.01398.x     Document Type: Article

References (24)

1. Bartlett RH, Andrews AF, Toomasian JM et al. Extracorporeal membrane oxygenation(ECMO) for newborn respiratory failure: 45 cases. Surgery 1982; 92: 425-433.
2. Levy FH, O'Rourke PP, Crone RK. Extracorporeal membrane oxygenation. Anesth Analg 1992; 75: 1053-1062.
3. Holley DG, Short BL, Kerr SS, et al. Mechanisms of change in cardiac performance in infants undergoing extracorporeal membrane oxygenation. Crit Care Med 1994; 22: 1865-1870.
4. Maack T. Receptors of atrial natriuretic factor. Ann Rev Physiol 1992; 54: 11-27.
5. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992; 86: 1081-1088.
6. Mills RM, Hobbs RE. How to use nesiritide in treating decompensated heart failure. Clev Clin J Med 2002; 69: 252-256.
7. Publication committee for VMAC investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287: 1531-1540.
8. Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis 2002; 44: 293-321.
9. Strauser LM, Pruitt RD, Tobias JD. Initial experience with fenoldopam in children. Am J Ther 1999; 6: 283-288.
10. Tobias JD, Pietsch JB, Lynch A. Nicardipine to control mean arterial pressure during extracorporeal membrane oxygenation. Paediatr Anaesth 1996; 6: 57-60.
11. Marshall J, Berkenbosch JW, Russo P et al. Preliminary experience with nesiritide in the pediatric population. J Intensive Care Med 2004; 19: 164-170.
12. Clemens LE, Ahnirez RG, Baudouin KA et al. Human brain natriuretic peptide reduces blood pressure in normotensive and acute norepinephrine-induced hypertensive rabbits. Am J Hypertens 1997; 10: 654-661.
13. Marcus LS, Hart D, Packer M et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo controlled, randomized cross over trial. Circulation 1996; 94: 3184-3189.
14. Abraham WT, Lowes BD, Ferguson DA et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998; 4: 37-44.
15. Akabane S, Matsushima Y, Matsuo H et al. Effects of brain natriuretic peptide on renin secretion in normal and hypertonic saline-infused kidney. Eur J Pharm 1991; 198: 143-148.
16. Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. New Engl J Med 2000; 343: 246-253.
17. Cooper HA, Dries DL, Davis CE et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100: 1311-1315.
18. Mehta RL, Rascual MT, Soroko S et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002; 288: 2547-2553.
19. Takeuchi M, Morita K, Iwasaki T et al. Significance of adrenomedullin under cardiopulmonary bypass in children during surgery for congenital heart disease. Acta Med Okayama 2001; 55: 245-252.
20. Huang MW, Scholtz PM, Weiss HR. Increases in myocardial cyclic GMP attenuate contractile delay in myocardial stunning. Can J Physiol Pharmacol 2002; 80: 804-810.
21. D'Souza SP, Yellon DM, Martin C et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 2003; 284: 1592-1600.
22. Rosen DA, Rosen KR. Elimination of drugs and toxins during cardiopulmonary bypass. J Cardiothor Vasc Anes 1997; 11: 337-340.
23. Burger AJ, Elkayam U, Neibaur MT et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001; 88: 35-39.
24. Burger AJ, Dennish G, Horton D et al. Nesiritide therapy for decompensated CHF is not proarrhythmic. J Am Coll Cardiol 2000; 35: 172-176.